Cargando…
Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model
Muscular dystrophies make up a group of genetic neuromuscular disorders that involve severe muscle wasting. TGF-β–activated kinase 1 (TAK1) is an important signaling protein that regulates cell survival, growth, and inflammation. TAK1 has been recently found to promote myofiber growth in the skeleta...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322678/ https://www.ncbi.nlm.nih.gov/pubmed/37071470 http://dx.doi.org/10.1172/jci.insight.164768 |
_version_ | 1785068810961682432 |
---|---|
author | Roy, Anirban Koike, Tatiana E. Joshi, Aniket S. Tomaz da Silva, Meiricris Mathukumalli, Kavya Wu, Mingfu Kumar, Ashok |
author_facet | Roy, Anirban Koike, Tatiana E. Joshi, Aniket S. Tomaz da Silva, Meiricris Mathukumalli, Kavya Wu, Mingfu Kumar, Ashok |
author_sort | Roy, Anirban |
collection | PubMed |
description | Muscular dystrophies make up a group of genetic neuromuscular disorders that involve severe muscle wasting. TGF-β–activated kinase 1 (TAK1) is an important signaling protein that regulates cell survival, growth, and inflammation. TAK1 has been recently found to promote myofiber growth in the skeletal muscle of adult mice. However, the role of TAK1 in muscle diseases remains poorly understood. In the present study, we have investigated how TAK1 affects the progression of dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). TAK1 is highly activated in the dystrophic muscle of mdx mice during the peak necrotic phase. While targeted inducible inactivation of TAK1 inhibits myofiber injury in young mdx mice, it results in reduced muscle mass and contractile function. TAK1 inactivation also causes loss of muscle mass in adult mdx mice. By contrast, forced activation of TAK1 through overexpression of TAK1 and TAB1 induces myofiber growth without having any deleterious effect on muscle histopathology. Collectively, our results suggest that TAK1 is a positive regulator of skeletal muscle mass and that targeted regulation of TAK1 can suppress myonecrosis and ameliorate disease progression in DMD. |
format | Online Article Text |
id | pubmed-10322678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-103226782023-07-07 Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model Roy, Anirban Koike, Tatiana E. Joshi, Aniket S. Tomaz da Silva, Meiricris Mathukumalli, Kavya Wu, Mingfu Kumar, Ashok JCI Insight Research Article Muscular dystrophies make up a group of genetic neuromuscular disorders that involve severe muscle wasting. TGF-β–activated kinase 1 (TAK1) is an important signaling protein that regulates cell survival, growth, and inflammation. TAK1 has been recently found to promote myofiber growth in the skeletal muscle of adult mice. However, the role of TAK1 in muscle diseases remains poorly understood. In the present study, we have investigated how TAK1 affects the progression of dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). TAK1 is highly activated in the dystrophic muscle of mdx mice during the peak necrotic phase. While targeted inducible inactivation of TAK1 inhibits myofiber injury in young mdx mice, it results in reduced muscle mass and contractile function. TAK1 inactivation also causes loss of muscle mass in adult mdx mice. By contrast, forced activation of TAK1 through overexpression of TAK1 and TAB1 induces myofiber growth without having any deleterious effect on muscle histopathology. Collectively, our results suggest that TAK1 is a positive regulator of skeletal muscle mass and that targeted regulation of TAK1 can suppress myonecrosis and ameliorate disease progression in DMD. American Society for Clinical Investigation 2023-05-22 /pmc/articles/PMC10322678/ /pubmed/37071470 http://dx.doi.org/10.1172/jci.insight.164768 Text en © 2023 Roy et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Roy, Anirban Koike, Tatiana E. Joshi, Aniket S. Tomaz da Silva, Meiricris Mathukumalli, Kavya Wu, Mingfu Kumar, Ashok Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model |
title | Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model |
title_full | Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model |
title_fullStr | Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model |
title_full_unstemmed | Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model |
title_short | Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model |
title_sort | targeted regulation of tak1 counteracts dystrophinopathy in a dmd mouse model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322678/ https://www.ncbi.nlm.nih.gov/pubmed/37071470 http://dx.doi.org/10.1172/jci.insight.164768 |
work_keys_str_mv | AT royanirban targetedregulationoftak1counteractsdystrophinopathyinadmdmousemodel AT koiketatianae targetedregulationoftak1counteractsdystrophinopathyinadmdmousemodel AT joshianikets targetedregulationoftak1counteractsdystrophinopathyinadmdmousemodel AT tomazdasilvameiricris targetedregulationoftak1counteractsdystrophinopathyinadmdmousemodel AT mathukumallikavya targetedregulationoftak1counteractsdystrophinopathyinadmdmousemodel AT wumingfu targetedregulationoftak1counteractsdystrophinopathyinadmdmousemodel AT kumarashok targetedregulationoftak1counteractsdystrophinopathyinadmdmousemodel |